ClinicalTrials.gov
ClinicalTrials.gov Menu

Radiation Therapy Cisplatin With or Without Fluorouracil Patients With Stage III or Stage IV Head and Neck Cancer

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00608205
Recruitment Status : Completed
First Posted : February 6, 2008
Results First Posted : September 19, 2013
Last Update Posted : October 21, 2016
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by (Responsible Party):
Case Comprehensive Cancer Center

Study Type: Interventional
Study Design: Allocation: Randomized;   Intervention Model: Parallel Assignment;   Masking: None (Open Label);   Primary Purpose: Treatment
Condition: Head and Neck Cancer
Interventions: Drug: cisplatin
Drug: fluorouracil
Radiation: radiation therapy

  Participant Flow

Recruitment Details
Key information relevant to the recruitment process for the overall study, such as dates of the recruitment period and locations
Patients recruited from Cleveland, Ohio medical clinics from December 2007 to August 2012.

Pre-Assignment Details
Significant events and approaches for the overall study following participant enrollment, but prior to group assignment
No text entered.

Reporting Groups
  Description
Arm A: Radiation With Concurrent Cisplatin Patients undergo full-dose radiotherapy once or twice daily 5 days a week for up to 7 weeks and receive cisplatin IV over 1 hour on days 1, 22, and 43 of radiotherapy.
Arm B: Radiation With Concurrent 5-FU and Cisplatin Patients undergo radiotherapy as in arm I and receive fluorouracil IV and cisplatin IV continuously on days 1-4 and 22-25 of radiotherapy.

Participant Flow:   Overall Study
    Arm A: Radiation With Concurrent Cisplatin   Arm B: Radiation With Concurrent 5-FU and Cisplatin
STARTED   35   34 
COMPLETED   32   31 
NOT COMPLETED   3   3 
Adverse Event                3                2 
Patient non-compliant                0                1 



  Baseline Characteristics


  Outcome Measures

1.  Primary:   Relapse Free Survival   [ Time Frame: at 2 yrs from start of study ]

2.  Secondary:   Patterns of Failure   [ Time Frame: 2 years from start of study ]

3.  Secondary:   Overall Survival   [ Time Frame: 2 yrs from start of study ]

4.  Secondary:   Number of Patients With a Clinical Response-complete Disappearance of Detectable Tumor   [ Time Frame: at 12 weeks after completing chemoradiotherapy ]

5.  Secondary:   Number of Patients With a Pathological(Final)Complete Response   [ Time Frame: at 12 weeks after completing chemoradiotherapy and surgery ]

6.  Secondary:   Disease Recurrence   [ Time Frame: 2 years after start of study ]

7.  Secondary:   Number of Patients That Required a Feeding Tube   [ Time Frame: 12 weeks (after treatment) ]

8.  Secondary:   Number of Patients That Required a Feeding Tube   [ Time Frame: 8 months after start of treatment ]

9.  Secondary:   Number of Patients That Required a Feeding Tube   [ Time Frame: 12 months after start of treatment ]

10.  Secondary:   Number of Patients That Required a Feeding Tube   [ Time Frame: 24 months after start of treatment ]

11.  Secondary:   Nausea Level   [ Time Frame: 12 weeks (after treatment) ]

12.  Secondary:   Nausea Level   [ Time Frame: 8 months from start of treatment ]

13.  Secondary:   Nausea Level   [ Time Frame: 12 months from start of treatment ]

14.  Secondary:   Nausea Level   [ Time Frame: 24 months from start of treatment ]

15.  Secondary:   Dry Mouth   [ Time Frame: 12 weeks (after treatment) ]

16.  Secondary:   Dry Mouth   [ Time Frame: 8 months from start of treatment ]

17.  Secondary:   Dry Mouth   [ Time Frame: 12 months from start of treatment ]

18.  Secondary:   Dry Mouth   [ Time Frame: 24 months from start of treatment ]

19.  Secondary:   Pain   [ Time Frame: 12 weeks (after treatment) ]

20.  Secondary:   Pain   [ Time Frame: 8 months from start of treatment ]

21.  Secondary:   Pain   [ Time Frame: 12 months from start of treatment ]

22.  Secondary:   Pain   [ Time Frame: 24 months from start of treatment ]

23.  Secondary:   Quality of Life   [ Time Frame: 12 weeks (after treatment) ]

24.  Secondary:   Quality of Life   [ Time Frame: 8 months from start of treatment ]

25.  Secondary:   Quality of Life   [ Time Frame: 12 months from start of treatment ]

26.  Secondary:   Quality of Life   [ Time Frame: 24 months from start of treatment ]

27.  Secondary:   Eating   [ Time Frame: 12 weeks (after treatment) ]

28.  Secondary:   Eating   [ Time Frame: 8 months from start of treatment ]

29.  Secondary:   Eating   [ Time Frame: 12 months from start of treatment ]

30.  Secondary:   Eating   [ Time Frame: 24 months from start of treatment ]

31.  Secondary:   Swallowing   [ Time Frame: 12 weeks (after treatment) ]

32.  Secondary:   Swallowing   [ Time Frame: 8 months after start of treatment ]

33.  Secondary:   Swallowing   [ Time Frame: 12 months after start of treatment ]

34.  Secondary:   Swallowing   [ Time Frame: 24 months after start of treatment ]

35.  Secondary:   Alcohol Consumption   [ Time Frame: 12 weeks (after treatment) ]

36.  Secondary:   Alcohol Consumption   [ Time Frame: 8 months after start of treatment ]

37.  Secondary:   Alcohol Consumption   [ Time Frame: 12 months after start of treatment ]

38.  Secondary:   Alcohol Consumption   [ Time Frame: 24 months after start of treatment ]

39.  Secondary:   Solid Foods   [ Time Frame: 12 weeks (after treatment) ]

40.  Secondary:   Solid Foods   [ Time Frame: 8 months after start of treatment ]

41.  Secondary:   Solid Foods   [ Time Frame: 12 months after start of treatment ]

42.  Secondary:   Solid Foods   [ Time Frame: 24 months after start of treatment ]


  Serious Adverse Events


  Other Adverse Events


  Limitations and Caveats

Limitations of the study, such as early termination leading to small numbers of participants analyzed and technical problems with measurement leading to unreliable or uninterpretable data
No text entered.


  More Information

Certain Agreements:  
All Principal Investigators ARE employed by the organization sponsoring the study.


Results Point of Contact:  
Name/Title: Dr. David Adelstein
Organization: Cleveland Clinic Taussig Cancer Institute, Case Comprehensive Cancer Center
phone: 216-444-9310
e-mail: adelstd@ccf.org



Responsible Party: Case Comprehensive Cancer Center
ClinicalTrials.gov Identifier: NCT00608205     History of Changes
Other Study ID Numbers: CASE3307
P30CA043703 ( U.S. NIH Grant/Contract )
NCI-2010-01197 ( Other Identifier: NCI/CTRP )
First Submitted: January 30, 2008
First Posted: February 6, 2008
Results First Submitted: July 11, 2013
Results First Posted: September 19, 2013
Last Update Posted: October 21, 2016